We are excited to unveil the LUPUS CORA 2027 abstract topics!

Building on the rapid advancements in the field, we are expanding the abstract list to provide dedicated space for a wider range of topics that need our focused attention.

To view the full abstract topics, please click on the buttons below for each category.

Each abstract must be assigned one of the following tracks and one of the following topics:

TRACKS

  • Basic and Translational Research
  • Clinical Research
  • Patient Perspective (PARE)
  • Pediatric

ABSTRACT TOPICS

  • Adaptive and innate immunity
  • Animal models
  • Antiphospholipid antibodies and antiphospolipid antibody syndrome
  • Biomarkers
  • Cardiovascular manifestations, infections and other comorbidities
  • Clinical manifestations
  • Diagnostic and classification criteria
  • Disease activity outcome measures, and treat-to-target
  • Epidemiology, quality of care, health economics
  • Etiology and pathogenesis
  • Family planning, fertility, pregnancy, lactation and neonatal care
  • Gender related aspects
  • Genetics and epigenetics
  • Lupus care around the world
  • Management and recommendations
  • New therapies, including biologics, targeted drugs, and cell therapies
  • Traditional therapies and glucocorticoids
  • Organ damage and survival
  • Other topics
  • Paediatric SLE and transition
  • Patient views and reported outcomes (PROMS)
  • Precision medicine
  • Rare manifestations
  • Difficult cases

Each abstract must be assigned one of the following tracks and one of the following topics:

🔹 PATHOGENESIS, IMMUNOLOGY AND ENVIRONMENTAL FACTORS

  • Etiology, genetics and mechanisms in rheumatic and autoimmune diseases
  • Environment, epigenetic and genetic
  • Innate and adaptive autoimmunity
  • IL17, TH17 and cytokines in autoimmunity
  • Immunometabolism and autoimmunity
  • Infection and autoimmunity
  • Pathogenetic and protective autoantibodies
  • Circulating extracellular vesicles
  • Microbiome, probiotic and nutritional factors in autoimmune and rheumatological diseases; Obesity and rheumatological diseases
  • COVID and autoimmunity
  • Pregnancy and autoimmunity; Prevention of autoimmune rheumatological diseases
  • Miscellaneous

🔹 DIAGNOSTICS, BIOMARKERS AND DATA-DRIVEN APPROACHES

  • Advances in autoantibody testing; Biomarkers in autoimmune rheumatological conditions
  • Omics and multi-omics in autoimmune and rheumatological diseases; Artificial intelligence in autoimmune rheumatological diseases
  • Registries and cohorts
  • Patient reported outcomes in autoimmune and rheumatological diseases

🔹 DISEASES AND ORGAN-SPECIFIC MANIFESTATIONS

Inflammatory Rheumatic Diseases

  • Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Spondyloarthritis; Spondyloarthropathies
  • Gout
  • Fibromyalgia, chronic pain and pain relief; Idiopathic inflammatory myopathies
  • Autoinflammatory diseases

Systemic Autoimmune Diseases

  • Systemic lupus erythematosus – clinical aspects, pathogenesis, therapies
  • Systemic sclerosis – clinical aspects and treatment, pathogenesis
  • Sjögren’s disease
  • Antiphospholipid syndrome
  • IgG4 related diseases
  • Vasculitis

Organ-specific involvement

  • Interstitial lung diseases; Pulmonary arterial hypertension & systemic sclerosis; Thyroid autoimmunity; Organ involvement in autoimmune rheumatic diseases

Special Populations

  • Pediatric rheumatology; Autoimmunity to the autonomic nervous system

🔹 THERAPEUTIC APPROACHES AND CLINICAL MANAGEMENT

  • Biological drugs; Small molecules and inhibitors; Novel therapeutic targets in rheumatological and autoimmune diseases; Novel aspects of therapies – biosimilars
  • CAR-T cells and autoimmune rheumatological diseases
  • Bispecific antibodies and rheumatological diseases
  • Checkpoint inhibitors induced autoimmunity
  • IVIG and natural autoantibodies
  • Refractory autoimmune diseases
  • Comorbidity in rheumatic and autoimmune diseases
  • Miscellaneous clinical management aspects

Click here for LUPUS CORA 2027 Abstracts Submission Guidelines.